Pennsylvania committee hears divergent testimony on House Bill 305 to cap insulin copays at $35 The House Insurance Committee heard personal and clinical testimony urging passage of House Bill 305 to cap a 30‑day supply of insulin at $35, while pharmacy benefit managers and insurers warned a universal cap could shift costs to insurers and raise premiums without addressing high list prices.

A Pennsylvania bill proposes to cap insulin costs at just $35 for a 30-day supply, but the debate reveals deep divides over the implications for patients and the healthcare system.

Click to read more!

#PA #PennsylvaniaInsulin #HealthcareAccess #CitizenPortal #ChronicDiseaseManagement